ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,417Medicare Part D Prescriptions Filled, Including Refills

Rank: 78 out of 1269

$530K Total Retail Price of All Prescriptions

Rank: 132 out of 1269

334 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
43% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 334 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

13% of this provider’s 334 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

0% of this provider’s 7,840 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LISINOPRIL 514 405 1 1
SIMVASTATIN 327 290 2 3
LEVOTHYROXINE SODIUM 324 303 3 4
METOPROLOL SUCCINATE 318 292 4 13
AMLODIPINE BESYLATE 312 287 5 2
FUROSEMIDE 251 225 6 5
OMEPRAZOLE 234 179 7 8
ATORVASTATIN CALCIUM 226 211 8 7
HYDROCODONE-ACETAMINOPHEN 192 123 S3 9 20
METOPROLOL TARTRATE 169 141 10 6
PANTOPRAZOLE SODIUM 163 134 11 18
POTASSIUM CHLORIDE 154 128 12 26
METFORMIN HCL 145 108 13 9
HYDROCHLOROTHIAZIDE 139 135 14 10
PRAVASTATIN SODIUM 136 113 15 11
TAMSULOSIN HCL 134 133 16 31
TRAMADOL HCL 125 113 17 16
GABAPENTIN 122 90 18 17
MIRTAZAPINE 121 98 19 24
PREDNISONE 120 107 20 45
ZOLPIDEM TARTRATE 118 95 21 19
LOSARTAN POTASSIUM 112 105 22 15
ALLOPURINOL 108 96 23 49
FLUTICASONE PROPIONATE 89 71 24 40
ADVAIR DISKUS 88 77 25 46
GLIMEPIRIDE 86 75 26 57
CLONIDINE HCL 82 82 27 51
WARFARIN SODIUM 81 71 28 12
CLOPIDOGREL 74 59 29 32
ISOSORBIDE MONONITRATE ER 74 56 29 63
TERAZOSIN HCL 73 58 31 111
DONEPEZIL HCL 73 73 31 22
NAMENDA 72 72 33 38
SERTRALINE HCL 68 59 34 23
RANITIDINE HCL 63 57 35 27
CITALOPRAM HBR 62 45 36 21
PROAIR HFA 61 43 37 61
KLOR-CON M20 61 52 37 60
NIFEDIPINE ER 58 43 39 65
ENALAPRIL MALEATE 57 57 40 79
CARVEDILOL 56 38 41 29
AZITHROMYCIN 55 42 42 42
FENOFIBRATE 52 47 43 115
METHYLPREDNISOLONE 52 39 43 154
TRAZODONE HCL 50 31 45 36
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 13, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.